Introducing a new series of reports

Business Insights have teamed up with global drug discovery experts to bring you a unique series of reports providing in-depth analysis into the future of the drug discovery sector. This new set of reports tackle the issues impeding innovation for R&D executives and assess the cutting edge approaches and technologies companies can use to overcome the productivity gap.

The R&D productivity crisis

In the last five years, on average, fewer than 30 NMEs (new molecular entities) per year have been approved in the US, despite record research and development spending. With key products suffering patent expiry in coming years, there is greater pressure on the pharmaceutical industry to resolve drug discovery bottlenecks and produce more innovative, efficacious and safe drugs.

Our new drug discovery portfolio of reports is designed to help R&D executives:

1. Minimize the bottlenecks in drug discovery
2. Utilize new technologies and advancement in bioinformatics, proteomics and genomics
3. Produce a pipeline of promising drug candidates

See diagram below for details of where our new reports can help you in the drug discovery process
 

 
Drug Discovery Series – report titles

• Commercial Opportunities from Biomarkers - OUT NOW
• Opportunities in Stem Cell Research - OUT NOW
• Lead Optimization Strategies - OUT NOW
• The Future of Array Technologies - OUT NOW
• The Future of Systems Biology - OUT NOW
• The Emerging Drug Targets Outlook - OUT NOW
• Predictive ADME and Toxicology Strategies - OUT NOW

Click here for further details and for the list of publications.

Global R&D spending was estimated at $38.8 billion in 2005 (PhRMA Annual Membership Survey 2005). Ensure your R&D investment provides the best return for your company by using this latest set of reports.